Bipolar Disorder - Current and Future Players

  • ID: 3756904
  • Report
  • 105 pages
  • GlobalData
1 of 4

FEATURED COMPANIES

  • Allergan
  • AstraZeneca
  • Dainippon Sumitomo
  • Eli Lilly
  • Janssen
  • Lundbeck
  • MORE
Bipolar Disorder - Current and Future Players

Summary

The author has released its pharma report, “Bipolar Disorder - Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Bipolar Disorder Market. The report identifies and analyses the key companies shaping and driving the global Bipolar Disorder market. The report provides insight into the competitive Bipolar Disorder landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by a team of industry experts.

Scope

- Investigation of current and future market competition for Bipolar Disorder
- Competitor assessment
- Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
- Strategic assessment of Bipolar Disorder sector through market impact analysis, future market scenario and company analysis

Reasons to buy

- Gain a high level view of the trends shaping and driving Bipolar Disorder market
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market
- What’s the next big thing in the global Bipolar Disorder market landscape? Identify, understand and capitalize
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Allergan
  • AstraZeneca
  • Dainippon Sumitomo
  • Eli Lilly
  • Janssen
  • Lundbeck
  • MORE
1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 Catalyst

2.2 Related Reports

2.3 Upcoming Related Reports

3 Market Outlook

3.1 Global Markets

3.1.1 Forecast

3.1.2 Drivers and Barriers - Global Issues

4 Current and Future Players

4.1 Overview

4.2 Trends in Corporate Strategy

4.3 Company Profiles

4.3.1 Otsuka

4.3.2 AstraZeneca

4.3.3 Eli Lilly

4.3.4 Allergan

4.3.5 Dainippon Sumitomo

4.3.6 Janssen

4.3.7 Lundbeck

4.3.8 Meiji Seika

5 Appendix

5.1 Bibliography

5.2 Abbreviations

5.3 Methodology

5.4 Forecasting Methodology

5.4.1 Diagnosed Bipolar Disorder Patients

5.4.2 Percent Drug-Treated Patients

5.4.3 Launch and Patent Expiry Dates

5.4.4 General Pricing Assumptions

5.4.5 Individual Drug Assumptions

5.4.6 Generic Erosion

5.5 Primary Research - KOLs Interviewed for this Report

5.6 Primary Research - Prescriber Survey

5.7 About the Authors

5.7.1 Analyst

5.7.2 Therapy Area Director

5.7.3 Epidemiologist

5.7.4 Global Director of Therapy Research and Analysis

5.8

5.9 Disclaimer

1.1 List of Tables

Table 1: Global Sales Forecast ($m) for Bipolar Disorder, 2014-2024

Table 2: Bipolar Disorder Market - Drivers and Barriers, 2014-2024

Table 3: Key Companies in the Bipolar Disorder Market in the 8MM, 2015

Table 4: Otsuka’s Bipolar Disorder Portfolio Assessment, 2015

Table 5: AstraZeneca’s Bipolar Disorder Portfolio Assessment, 2015

Table 6: Eli Lilly’s Bipolar Disorder Portfolio Assessment, 2015

Table 7: Allergan’s Bipolar Disorder Portfolio Assessment, 2015

Table 8: Dainippon Sumitomo’s Bipolar Disorder Portfolio Assessment, 2015

Table 9: Janssen Bipolar Disorder Portfolio Assessment, 2015

Table 10: Lundbeck Bipolar Disorder Portfolio Assessment, 2015

Table 11: Meiji Seika Bipolar Disorder Portfolio Assessment, 2015

Table 12: Key Launch Dates

Table 13: Key Patent Expiries

Table 14: High-Prescribing Physicians (Non-KOLs) Surveyed, By Country

1.2 List of Figures

Figure 1: Global Sales for Bipolar Disorder by Region, 2014-2024

Figure 2: Global Sales for Bipolar Disorder by Drug Class, 2014-2024

Figure 3: Global Sales of Products for Bipolar Disorder by Company, 2014-2024

Figure 4: Company Portfolio Gap Analysis in Bipolar Disorder, 2014-2024

Figure 5: Otsuka SWOT Analysis in Bipolar Disorder, 2014-2024

Figure 6: AstraZeneca SWOT Analysis in Bipolar Disorder, 2014-2024

Figure 7: Eli Lilly SWOT Analysis in Bipolar Disorder, 2014-2024

Figure 8: Allergan SWOT Analysis in Bipolar Disorder, 2014-2024

Figure 9: Dainippon Sumitomo SWOT Analysis in Bipolar Disorder, 2014-2024

Figure 10: Janssen SWOT Analysis in Bipolar Disorder, 2014-2024

Figure 11: Lundbeck SWOT Analysis in Bipolar Disorder, 2014-2024

Figure 12: Meiji Seika SWOT Analysis in Bipolar Disorder, 2014-2024
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Otsuka
AstraZeneca
Eli Lilly
Allergan
Dainippon Sumitomo
Janssen
Lundbeck
Meiji Seika
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll